KDNY earnings

Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with IgAN across Cohorts 1 and 2Zigakibart is well-tolerated, with no ADAs observed or treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2 In all patients combined from both Cohorts 1 and 2, zigakibart demonstrated mean proteinuria reductions of 20% at 12 weeks of treatment, 39% at 24 weeks of treatment and 67% at 52 weeks of treatmentExtended treatment with zigakibart resulted in sustained clinical benefit, with 67% mean proteinuria

Updated interim data to be presented from Cohort 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgANInitial data to be presented from the phase 1 study of CHK-336 in healthy volunteersAdditional presentations on the design of the phase 2 ASSIST study for atrasentan in patients with IgAN on background RASi and SGLT2i and the phase 3 BEYOND study of BION-1301 in patients with IgAN, as well as research on the impact of maladaptive tubular epithelial cells on disease progression in chronic kidney diseasesChinook to host investor conference call and webcast on June 16, 2023 at 8:15 am EDT to review and discuss the presentations and provide corporate updates SEATTLE, May 05

The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2BION-1301 continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, in patients with IgAN across Cohorts 1 and 2In Cohort 1, BION-1301 demonstrated mean proteinuria reductions of 30.4% at 12 weeks of treatment, 48.8% at 24 weeks of treatment and 66.9% at 52 weeks of treatment, as well as 6

Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment There were no meaningful changes in blood pressure or acute eGFR, suggesting proteinuria reductions were not primarily due to hemodynamic effects of atrasentan, and there were no increases in brain natriuretic peptide (BNP) or mean bodyweight, suggesting minimal fluid retention Preclinical data was presented on single-cell RNA-seq of a mouse model of IgAN, revealing a prominent expansion of failed repair proximal tubular epithelial cells, wh

Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Research presentations include the preclinical efficacy profile of CHK-336 and multiple abstracts detailing Chinook's multidimensional approach to precision medicine in nephrology Chinook to host investor conference call and webcast on November 4, 2022 to review and discuss the abstracts and provide corporate updates SEATTLE, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company foc

The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representing an IgAN patient population at high risk for progressionAtrasentan was well-tolerated with no treatment-related serious adverse events (SAEs)Atrasentan demonstrated 38.0% proteinuria reduction at six weeks of treatment, 49.9% proteinuria reduction at 12 weeks of treatment and 58.5% reduction at 24 weeks of treatmentThere were no meaningful changes in blood pressure or acute eGFR, suggesting proteinuria reductions were not primarily due to hemodynamic effects of atrasentan, and there were no increase

All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs)BION-1301 continues to demonstrate rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levelsBION-1301 demonstrated ~50% proteinuria reduction in patients with IgAN after three to six months of treatment, with ~70% reductions observed in six patients at one year and in two patients at 1.5 years of treatmentPreclinical mechanistic data was presented, describing atrasentan's effect to block mesangial cell injury a

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. "During the first quarter of 2022, we made strong progress advancing our pipeline of clinical, research and discovery programs for rare, severe chronic kidney diseases. We continue to enroll patients in the phase 3 ALIGN and phase 2 AFFINITY trials for atrasentan as well as the phase 1/2 trial of BION-1301, and we are pleased to have recently initiated the phase 1 health

Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trialUpdated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgANAdditional abstracts to be presented include atrasentan's mechanism to block mesangial cell injury and the pathogenic transcriptional networks driving IgAN progression in a translational model, as well as a systems nephrology framework for the molecular classification of chronic kidney disease to fuel Chinook's precision medicine strategy through the Evotec collaborationChinook to host investor conference call and webcast on May 20, 202

BION-1301 was well-tolerated and demonstrated rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levelsBION-1301 demonstrated >50% proteinuria reduction in patients with IgAN after three to six months of treatment, with further reductions in two patients through one year of treatmentAdditional data was presented on the atrasentan program, including translational research demonstrating ETA activation is associated with clinical progression in IgANChinook to host investor conference call and webcast today at 4:30 pm EDT with Jonathan Barratt, MChB, PhD, Mayer Professor of Renal Medicine at University of Leicester, and Laura Koo

Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions Several presentations on the atrasentan clinical program, including translational research demonstrating ETA activation is associated with clinical progression in IgA nephropathy Chinook to host investor conference call and webcast on November 4, 2021 to review abstracts and provide updates on the company's pipeline SEATTLE, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney disea